Patient screening has resumed following temporary suspension due to escalation of the COVID-19 pandemic
Data readout from the Phase 2 cognitive impairment study expected in 2H 2022
Three Phase 2 data readouts expected over the next 12 to 18 months across the company’s clinical development pipeline
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has recommenced patient screening in a Phase 2 study of NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson’s disease and dementia with Lewy bodies. The company anticipates reporting data from this study in the second half of 2022.
https://finance.yahoo.com/news/aptinyx-recommences-phase-2-study-103700276.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.